#Profound ai icad software#
The software also improves workflow issues, as we’re able to more quickly navigate through DBT datasets.” Lynn Women’s Health & Wellness Institute at the Boca Raton Regional Hospital, “ProFound AI for DBT rapidly and accurately analyze patients’ DBT mammography images, identifying suspicious lesions and producing quantifiable AI scores, which enables us to identify cancers earlier. Specifically, our high-performing cancer detection and workflow solution offers the highest cancer detection rate, the lowest false positive rate and a dramatic 52.7% reduction in radiologists’ reading time, representing a high level of clinical significance and advantage.”Īccording to Kathy Schilling, MD, Medical Director of the Christine E. Of significant note is that no other breast AI solution has been shown to improve radiologists’ clinical performance when reading DBT more so than ProFound AI. “We do so on a non-exclusive, open architecture basis, therefore allowing all global customers access to the best of breed AI software available.
#Profound ai icad full#
“iCAD offers the full continuum of breast health AI products-both for the detection of current breast cancers and for future risk assessment,” said Michael Klein, Chairman and CEO of iCAD. The solid momentum is led by the Company’s growing customer base and demand for its expanded suite of leading breast health AI solutions, including ProFound AI for both Digital Breast Tomosynthesis (DBT) and 2D mammography, and interest in the recently introduced ProFound AI Risk, which is helping to transform breast cancer screening from age-based screening to risk-adapted precision screening, individualized for each woman. The sales have been distributed across all major mammography system vendors and enterprise-wide viewing applications with a significant percentage to date sold to hospitals and imaging centers with GE and Siemens, as well as facilities with more than one imaging system vendor, including Hologic and Fuji. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported that over 1,000 licenses have been sold as part of ProFound AI® sales since the products were launched, signaling the rapid and wide-spread adoption of the pioneering cancer detection software solution built on artificial intelligence (AI). ProFound AI for DBT Offers Superior Clinical Performance When Compared to Other Commercially Available Breast AI Systems
Many of these cancers are diagnosed as interval breast cancers, defined as those that emerge after a normal mammogram but before the woman’s next scheduled screening.Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji Regular, age-based mammography screening reduces breast cancer mortality by approximately 20%, but screening mammography can still miss 20 to 40% of breast cancers. This solution, now available for tomosynthesis, provides an accurate estimate of the risk of short-term breast cancer, which is truly personalized for each woman.
In addition, the new version of ProFound AI Risk will also be available for demonstration at the iCAD booth at JFR. "By using this leading-edge technology, both general and breast radiologists can potentially improve their accuracy and performance, which may in turn have a positive impact on women and the healthcare system overall." "The European launch of our third generation of ProFound AI for 2D Mammography demonstrates iCAD’s steadfast commitment to improving breast cancer detection for all women worldwide," said President Stacey Stevens. In addition, the company, based in Nashua, New Hampshire, will showcase its most recent technological advancements, including the latest generations of ProFound AI® for Digital Breast Tomosynthesis (DBT) and ProFound AI® Risk, in its booth. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will unveil the latest generation of ProFound AI® for 2D Mammography at the Journées Francophones de Radiologie (JFR) meeting in Paris, Friday through Monday.
0 kommentar(er)
